{"entity":{"id":"masofaniten","kind":"drug","name":"Masofaniten","aka":[],"tldr":"A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended.","summary":"ESSA Pharma terminated the phase 2 of masofaniten + enzalutamide in mCRPC (2024) after a futility analysis on PSA90; the company later discontinued development (2025). The EXTRA-PC investigator trial in mHSPC closed early. AR-NTD inhibition remains unproven clinically despite compelling biology (AR-V7).","status":"withdrawn","asOf":"2026-09-06","links":[{"label":"ESSA terminates phase 2 (OncLive)","url":"https://www.onclive.com/view/essa-discontinues-phase-2-study-of-masofaniten-plus-enzalutamide-in-mcrpc"}],"tags":["failed-so-far"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["androgen-receptor"],"drugs":[],"companies":["essa-pharma"],"institutions":[],"pathways":[],"terms":["ar-v7"],"trials":["nct06312670"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"EPI-7386","modality":"Small-molecule AR N-terminal domain inhibitor","mechanism":"Binds the disordered N-terminal domain of AR, intended to inhibit full-length and splice-variant AR.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/masofaniten/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"company":[{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/"}],"term":[{"id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/"}],"trial":[{"id":"nct06312670","kind":"trial","name":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","route":"/trials/nct06312670/"}]}}